Company Description
Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action.
The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues.
Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer.
The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy.
It has a license agreement with New Life Therapeutics PTE, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin 6.
Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.
| Country | United States |
| IPO Date | Oct 31, 2006 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 12 |
| CEO | Dr. Pankaj Mohan Ph.D. |
Contact Details
Address: 100 Overlook Center Princeton, New Jersey United States | |
| Website | https://www.sonnetbio.com |
Stock Details
| Ticker Symbol | SONN |
| Exchange | NASDAQ |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0001106838 |
| CUSIP Number | 83548R105 |
| ISIN Number | US83548R3030 |
| Employer ID | 52-2102141 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Pankaj Mohan Ph.D. | Founder, Chairman, Chief Executive Officer & President |
| Dr. Gael Hedou Ph.D. | Chief Operating Officer |
| Jay Cross | Chief Financial Officer |
| Donald J. Griffith CPA, CPA | Financial Controller & Director |
| Dr. John K. Cini Ph.D. | Chief Scientific Officer & Co-Founder |
| Dr. Richard T. Kenney FACP, M.D. | Chief Medical Officer |
| Dr. Stephen J. McAndrew Ph.D. | Senior Vice President of Business Development |
| Manuel Dafonseca | Head of Clinical Operations |
| Susan Dexter | Chief Technical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 23, 2024 | D | Filing |
| Dec 17, 2024 | 10-K | Annual Report |
| Dec 17, 2024 | 8-K | Current Report |
| Dec 10, 2024 | 8-K | Current Report |
| Dec 10, 2024 | 424B5 | Filing |
| Dec 09, 2024 | 8-K | Current Report |
| Dec 05, 2024 | 4 | Filing |
| Dec 05, 2024 | 4 | Filing |
| Dec 05, 2024 | 4 | Filing |
| Dec 05, 2024 | 4 | Filing |